.jetcityimage/iStock Content using Getty Images Morgan Stanley has actually selected Eli Lilly (NYSE: LLY) as its leading biopharma selection for 2025 and also measured yet another nine names in the room as overweight. The financial investment bank said in a note that it remains to feel “diabesity is actually set to come to be.